Bioaffinity Technologies, INC 8-K filings

BioAffinity Technologies has issued 1.6 million shares of common stock and warrants, leading to an adjustment in the exercise price of its existing IPO warrants.

bioAffinity Technologies has successfully raised $2.5 million through a registered direct offering of common stock and a concurrent private placement of warrants.

bioAffinity Technologies announced a 375% increase in CyPath Lung test orders over the past three months, driven by physician interest and a new reimbursement code.

BioAffinity Technologies has adopted a new management incentive bonus plan and approved cash and stock bonuses for several executives.